Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | MC4R | P32245 | 2/20 | 0.48 |
| ▸ | MC5R | P33032 | 2/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429589 | 0.85 | GPR84 (0.52) | CNR2GPR84KDRMC4RMC5R | |
| SCHEMBL6327424 | 0.84 | GPR84 (0.60) | CNR2GPR84KDRNR4A2CREBBP | |
| SCHEMBL8530849 | 0.83 | GPR84 (0.77) | CNR2GPR84NR4A2CREBBPPBRM1 | |
| SCHEMBL29489280 | 0.83 | GPR84 (0.77) | CNR2GPR84NR4A2CREBBPPBRM1 | |
| SCHEMBL6402031 | 0.81 | SMN1; SMN2 (0.63) | CNR2GPR84KDRGABRA1GABRB2 | |
| SCHEMBL6401553 | 0.75 | GPR84 (0.68) | CNR2GPR84CFTRNR4A2CREBBP | |
| SCHEMBL2028344 | 0.75 | GPR84 (1.00) | GPR84NR4A2CREBBPPBRM1PIM1 | |
| SCHEMBL6325416 | 0.74 | CNR2 (0.53) | CNR2CDC25B | |
| SCHEMBL6323376 | 0.74 | NR4A1 (0.55) | CNR2NR4A2CDC25B | |
| SCHEMBL5990471 | 0.74 | CDC25B (0.56) | CNR2CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CLEMSON UNIVERSITY | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CNR2, CNR1, GPR68 | CNR2 1/4885GPR84 47/4885KDR 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.